ISM-6331

The primary purpose of this trial is to evaluate the safety and tolerability of ISM6331 in subjects with advanced or metastatic malignant mesothelioma or other solid tumors and to determine the recommended dose for Phase II. The secondary purpose of this trial is to evaluate the pharmacokinetic (PK) characteristics of ISM6331 in plasma after single and multiple doses of ISM6331 and to evaluate the preliminary efficacy of ISM6331 monotherapy. The exploratory purpose of this trial is to evaluate the pharmacodynamic (PD) effects and potential predictive biomarkers of ISM6331 and to explore the metabolites of ISM6331.